Heart failure & cardiomyopathiesCohort study
Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy
- Retrospective cohort study
- multicentre
- observational
- longitudinal
- consecutive patients
Authors' conclusion
Among HCM phenotypes, the prognosis of patients with end-stage HCM was markedly worse. The 2024 ACC/AHA and 2023 ESC guidelines well stratified SCD risk in patients with HCM; the 2024 ACC/AHA guidelines seemed to better stratify SCD risk between Classes 2a and 2b compared with the 2023 ESC guidelines.
Study context
- Population
- Consecutive patients with hypertrophic cardiomyopathy, large-scale Japanese multicentre registry
- Participants
- 3,611 patients
- Exposure
- Sudden cardiac death (SCD) risk by hypertrophic cardiomyopathy (HCM) phenotype and by guideline recommendation class
- Outcome
- Composite of:
- SCD
- An equivalent event
Main finding
As reported in the abstract
5-year cumulative incidence of SCD events by HCM phenotype · 5 years
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| 5-year cumulative incidence of SCD events by recommendation class, 2024 ACC/AHA guidelines · not well stratified | Class 1 23.8% · Class 2a 7.2% · Class 2b 5.7% · Class 3 2.3% | P = 0.101 |
| 5-year cumulative incidence of SCD events by recommendation class, 2023 ESC guidelines · event rate reversed | Class 1 23.8% · Class 2a 2.9% · Class 2b 9.3% · Class 3 2.6% | P = 0.545 |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy. JACC Heart Fail. Published 12 March 2025. doi:10.1016/j.jchf.2024.12.006
Summarised from the published abstract; every number is checked against it